Close

Wedbush Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition

December 3, 2019 6:49 AM EST Send to a Friend
Wedbush analyst David Nierengarten downgraded Audentes Therapeutics (NASDAQ: BOLD) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login